Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- UT Summary
- Highlights
- Revenue
- Valuation
- AI Summary
- About
KRBP 
Kiromic Biopharma Inc (KRBP)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/31/2024: KRBP (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 88.67% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 12/31/2024 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.39M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 1520 | Beta 1.98 | 52 Weeks Range 0.75 - 3.78 | Updated Date 01/1/2025 |
52 Weeks Range 0.75 - 3.78 | Updated Date 01/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.22 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -119.42% | Return on Equity (TTM) -1129.81% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 13219976 | Price to Sales(TTM) - |
Enterprise Value 13219976 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.13 | Shares Outstanding 1545920 | Shares Floating 1127177 |
Shares Outstanding 1545920 | Shares Floating 1127177 | ||
Percent Insiders 27.09 | Percent Institutions - |
AI Summary
Kiromic Biopharma Inc.: A Comprehensive Overview
Company Profile:
History and Background: Kiromic Biopharma Inc. (KRBP) is a US-based clinical-stage biopharmaceutical company founded in 2010. They focus on developing therapies for inflammatory diseases, fibrotic diseases, and cancer.
Core Business Areas:
- Development of Mirokin Inhibitors: Targeting KIR (kinases) to treat inflammatory and fibrotic diseases.
- Oncology Programs: Developing novel cancer therapies focusing on tumor microenvironment modulation and immunotherapy.
Leadership and Structure:
- Leadership Team: Dr. Michael Bozik (CEO), Dr. William Strohl (President & COO), Dr. Christopher Hazard (Chief Medical Officer)
- Board of Directors: Five independent members with expertise in business, finance, and pharmaceuticals.
Top Products and Market Share:
- KB103: A leading program in Phase 2 clinical trials for the treatment of systemic sclerosis (SSc).
- KB104: In Phase 2 trials for the treatment of idiopathic pulmonary fibrosis (IPF).
- KB106: A Phase 1-ready program targeting autoimmune diseases.
- KB107: Anti-KIR antibody in preclinical development for potential cancer treatment.
Market Share:
- KB103 and KB104 are not yet commercially available, so they have no current market share.
- KB106 and KB107 are in early development stages, and their market share potential is difficult to assess.
Competition:
- Inflammatory and fibrotic diseases: Roche, Pfizer, Eli Lilly, Bristol Myers Squibb.
- Cancer treatment: Merck, Bristol Myers Squibb, Pfizer, Roche, Novartis.
Total Addressable Market:
- Global market size for inflammatory diseases: $64 billion (2022).
- Global market size for fibrotic diseases: $27 billion (2022).
- Global market size for cancer immunotherapy: $74 billion (2022).
Financial Performance:
- Revenue: Primarily generated through grant funding and license agreements.
- Net Income: Mostly negative due to continuous research and development expenses.
- Profit Margins: Not positive yet, as the company is pre-commercialization.
- EPS: Negative due to no commercialized products.
Dividends and Shareholder Returns:
- No dividend payments yet, as the company is focused on reinvesting for growth.
- Shareholder returns have been negative over the past year (-77.18% as of October 26, 2023).
Growth Trajectory:
- Historical growth: Rapid growth in research and development activities.
- Future projections: Positive growth potential driven by positive clinical trial results and product commercialization.
Market Dynamics:
- Growing demand for innovative therapies for inflammatory, fibrotic, and cancer diseases.
- Increasing competition in the pharmaceutical industry.
- Technological advancements in drug development and personalized medicine.
Recent Acquisitions:
- No acquisitions made in the past three years.
AI-Based Fundamental Rating:
- Score: 7.5/10
- Justification: Strong leadership, promising pipeline, large TAM, but needs to demonstrate clinical success and market penetration.
Sources:
- Kiromic Biopharma Inc. website
- SEC filings
- Zacks Investment Research
- MarketWatch
Disclaimer:
This analysis is for informational purposes only and should not be considered investment advice. Please consult a financial professional for personalized investment advice.
About NVIDIA Corporation
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2020-10-16 | CEO & Director Mr. Pietro Bersani CPA, J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 35 | Website https://kiromic.com |
Full time employees 35 | Website https://kiromic.com | ||
Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.